应用预制牛心包移植物治疗主髂动脉及腹股沟下血管感染
本研究回顾性分析2020年10月至2023年2月间20例原生或人工血管主髂动脉及腹股沟下感染患者,采用预制牛心包移植物行原位重建,并遵循标准化术后抗凝及长期静脉抗生素方案。院内死亡率为5%(n=1),移植物相关死亡率为0%;中位随访13个月(范围6-34个月)再感染率为5.2%,原发移植物通畅率为94.7%。作者认为该预制牛心包移植物是治疗此类感染的有前景的选择。
要点
- 20例主髂动脉及腹股沟下血管感染患者使用预制牛心包移植物行原位重建。
- 院内死亡率5%(n=1),移植物相关死亡率为0%。
- 中位随访13个月,再感染率5.2%,原发移植物通畅率94.7%。
核心结论
- 使用预制牛心包移植物是治疗原生或人工血管主髂动脉及腹股沟下感染的有前景的选择。
- 应用该生物移植物并遵循标准化术后方案,与满意的通畅率和再感染率相关,且不增加出血并发症。
研究设计与样本
- 回顾性分析2020年10月至2023年2月在意大利罗马Fondazione Policlinico Universitario Gemelli - IRCCS血管外科单位接受Biointegral Surgical No-React牛心包移植物原位重建的20例原生或人工血管主髂动脉及腹股沟下感染患者。
- 所有患者遵循标准化方案,包括术后抗凝和长期静脉抗生素治疗。
主要发现
- 手术指征为:真菌性主动脉瘤4例(20%),腹主动脉修复后移植物感染11例(55%),外周移植物感染5例(25%)。
- 所有患者均行感染主动脉或人工血管的完全切除、外科清创和原位重建。
- 院内死亡率为5%(n=1),移植物相关死亡率为0%。
- 随访期间(中位13个月,范围6-34个月),再感染率为5.2%,原发移植物通畅率为94.7%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of biological grafts provides acceptable mid- and long-term results in native or prosthetic vascular infections. Several reports describe the successful use of bovine pericardium in case of vascular infections, mainly as a large patch to be sutured as a tubular graft. Recently, a novel prefabricated bovine pericardium graft (Biointegral Surgical No-React® Inc, Mississauga, ON, Canada) has been introduced in clinical practice with promising results. In this study, we report our preliminary experience utilizing Biointegral Surgical graft in case of native and or prosthetic aorto-iliac and infrainguinal infection. METHODS: We retrospectively analyzed data from 20 patients with native or prosthetic aorto-iliac and infrainguinal infection who underwent in situ reconstruction (ISR) with a Biointegral Surgical No-React bovine pericardium prosthesis between October 2020 and February 2023 at the Vascular Surgery Unit of the Fondazione Policlinico Universitario Gemelli - IRCCS in Rome, Italy. All patients followed a standardized protocol including postoperative anticoagulation and long-term intravenous antibiotics. RESULTS: The indication for surgery was: mycotic aortic aneurysm in 4 patients (20%), graft infection after abdominal aortic repair in 11 patients (55%), peripheral graft infection in 5 patients (25%). Complete excision of the infected aorta or prosthetic graft, surgical debridement and ISR were performed in all patients. Hospital mortality rate was 5% (n = 1) and graft-related mortality of 0%. During follow-up (median 13 months, range 6-34 months), reinfection was 5.2% and primary graft patency 94.7%. CONCLUSIONS: The use of prefabricated bovine pericardial grafts represents a promising option for the treatment of native and prosthetic aorto-iliac and infrainguinal infections. The application of this biological graft with a standardized postoperative protocol has been associated with a satisfactory patency and reinfection rate without increased bleeding complications.
引用
- Donato F, Donati T, Minelli F, et al. Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft. Ann Vasc Surg. 2024. PMID: 38599483. doi:10.1016/j.avsg.2024.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。